Single-session combined therapy with chemoembolization and DSA-CT guided radiofrequency ablation in hepatocellular carcinoma larger than 5 cm: A primary clinical study

doi:10.3877/cma.j.issn.2095-5782.2014.02.004

Abstract

Abstract:

Objective

To assess the safety and efficacy of single-session combined therapy with transcatheter arterial chemoembolization (TACE) and DSA-CT guided radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) larger than 5 cm.

Methods

A total of 21 patients were treated with TACE immediately followed by DSA-CT-guided RFA. Rate of technical success, local-regional tumor response, recurrence-free survival time, survival rate and complications were evaluated at follow-up images and AFP (α-fetoprotein).

Results

Technical success was achieved in all 25 visible HCC. No major complications was observed in any patient. Nineteen patients were complete response (CR) and 2 were partial response (PR) after the 1st months. Coagulation necrosis was the major appearance. CR occupied 90.48% (19/21). PR occupied 9.52% (2/21). Local-regional tumor response in solitary nodular lesions (17/17, 100%) was superior to multiple nodular lesions (2/4, 50.00%; P=0.034). During follow-up period, mean recurrence-free survival time was 11.8±6.0 months in 19 cases with CR. The estimated overall survival rate at 6, 12 months and 18 months was 100%.

Conclusions

Single-session combined therapy with TACE and DSA-CT guided RFA in large hepatocellular carcinoma was safe and effective, especially for solitary nodular lesions.

Key words: Carcinoma, hepatocellular, Chemoembolization, therapeutic, Catheter ablation, Single-session

Zhijun Wang, Maoqiang Wang, Feng Duan, Peng Song, Fengyong Liu, Yan Wang, Jieyu Yan, Kai Li. Single-session combined therapy with chemoembolization and DSA-CT guided radiofrequency ablation in hepatocellular carcinoma larger than 5 cm: A primary clinical study[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2014, 02(02): 13-18.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2014.02.004

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2014/V02/I02/13

Figures/Tables 4

References 22

1	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822):1245-1255.
2	Marín-Hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results[J]. Crit Rev Oncol Hematol, 2003,47(1): 13-27.
3	Takaki H,Yamakado K, Uraki J, et al.Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm[J]. J Vasc Interv Radiol, 2009,20(2):217-224.
4	Georgiades CS, Hong K, Geschwind JF, et al. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma[J]. Cancer J, 2008,14(2):117-122.
5	Miyayama S, Yamashiro M, Okuda M, et al. Chemoembolization for the treatment of large hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2010,21(8):1226-1234.
6	Fan WZ, Yang JY, Lü MD, et al. Transcatheter arterial chemoembolization plus percutaneous thermal ablation in large hepatocellular carcinoma: clinical observation of efficacy and predictors of prognostic factors[J]. Zhonghua Yi Xue Za Zhi, 2011,91(31):2190-2194.
7	Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology[J]. J Vasc Interv Radiol, 2002,13(12):1225-1232.
8	Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis[J]. Liver Int, 2010,30(5):741-749.
9	Yamakado K, Nakatsuka A, Takaki H, et al. Subphrenic versus nonsubphrenic hepatocellular carcinoma: combined therapy with chemoembolization and radiofrequency ablation[J]. AJR Am J Roentgenol, 2010,194(2):530-555.
10	赵敏，王健鹏，吴沛宏，等. TACE与TACE联合RFA治疗中晚期原发性肝癌167例临床对比分析[J]. 中华医学杂志，2010, 90(41):2916-2921.
11	Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001,35(3): 421-430.
12	Takaki H, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression[J]. J Vasc Interv Radiol, 2007,18(7):856-861.
13	Shimada K, Sakamoto Y, Esaki M, et al. Role of a hepatectomy for the treatment of large hepatocellular carcinomas measuring 10 cm or larger in diameter[J]. Langenbecks Arch Surg, 2008,393(4):521-526.
14	Zangos S, Eichler K, Balzer JO, et al. Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT)[J]. Eur Radiol, 2007,17(2): 553-563.
15	Gadaleta C, Catino A, Ranieri G, et al. Single-step therapy-- feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies[J]. In Vivo, 2009,23(5):813-820.
16	Kang SG, Yoon CJ, Jeong SH, et al. Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study[J]. J Vasc Interv Radiol, 2009,20(12):1570-1577.
17	Shiraishi R, Yamasaki T, Saeki I, et al. Pilot study of combination therapy with transcatheter arterial infusion chemotherapy using iodized oil and percutaneous radiofrequency ablation during occlusion of hepatic blood flow for hepatocellular carcinoma[J]. Am J Clin Oncol, 2008,31(4):311-316.
18	Dhanasekaran R, Kooby DA, Staley CA, et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)[J]. J Surg Oncol. 2010,101(6):476-480.
19	Head HW, Dodd GD 3rd, Bao A, et al. Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors[J]. Radiology, 2010,255(2):405-414.
20	Lee MW, Kim YJ, Park SW, et al. Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation[J]. Br J Radiol, 2009,82(983):908-915.
21	Lee MW, Kim YJ, Park SW, et al. Biplane fluoroscopy-guided radiofrequency ablation combined with chemoembolisation for hepatocellular carcinoma: initial experience[J]. Br J Radiol, 2011, 84(1004):691-697.
22	范文哲，杨建勇，吕明德, 等. TACE联合经皮热消融治疗大肝癌的疗效及预后分析[J]. 中华医学杂志，2011, 91(31):2190-2194.

参数		数值
年龄[范围（平均），岁]		38~67（48.3±9.4）
性别[例（%）]		?
?	男性	17（81%）
?	女性	4（19%）
Child–Pugh分级[例（%）]		?
?	A	16（76%）
?	B	5（24%）
肝硬化病因[例（%）]		?
?	乙肝	14（67%）
?	丙肝	5（23%）
?	乙肝合并丙肝	2（10%）
甲胎蛋白（ng/ml）[例（%）]		?
?	≤20	8（38%）
?	>20	13（62%）
病灶部位[例（%）]		?
?	近膈下	9 （43%）
?	非膈下	16 （57%）
最大直径[例（%）]		?
?	5~10 cm	16（57%）
?	>10 cm	9（43%）
病灶个数		?
?	1个	17
?	2个	4
既往TACE情况（例）		?
?	1次	10
?	2次	6
?	3次	3
?	4次	2

参数		数值
年龄[范围（平均），岁]		38~67（48.3±9.4）
性别[例（%）]		?
?	男性	17（81%）
?	女性	4（19%）
Child–Pugh分级[例（%）]		?
?	A	16（76%）
?	B	5（24%）
肝硬化病因[例（%）]		?
?	乙肝	14（67%）
?	丙肝	5（23%）
?	乙肝合并丙肝	2（10%）
甲胎蛋白（ng/ml）[例（%）]		?
?	≤20	8（38%）
?	>20	13（62%）
病灶部位[例（%）]		?
?	近膈下	9 （43%）
?	非膈下	16 （57%）
最大直径[例（%）]		?
?	5~10 cm	16（57%）
?	>10 cm	9（43%）
病灶个数		?
?	1个	17
?	2个	4
既往TACE情况（例）		?
?	1次	10
?	2次	6
?	3次	3
?	4次	2

病灶类型	肿瘤彻底灭活能力		合计
病灶类型	CR	PR	合计
单结节型	17	0	17
多结节型	2	2	4
合计	19	2	21

病灶类型	肿瘤彻底灭活能力		合计
病灶类型	CR	PR	合计
单结节型	17	0	17
多结节型	2	2	4
合计	19	2	21

[1]	Yumeng Zheng, Mingyan Ding, Lijuan Guo, Huihui Zhang, LiYing, Hanzhang Zhao, Fang Zhu. Evaluation of left atrial structural and function by echocardiography in patients with atrial fibrillation after combined catheter ablation and left atrial appendage closure [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(12): 1336-1341.
[2]	Tingting Wu, Xiang Xie, Fan Jiang, Sihua Fang, Ping Hu, WenChi. Guo. Evaluation of left ventricular myocardial work by pressure-strain loop in atrial fibrillation patients with normal left ventricular ejection fraction before and after catheter ablation [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(12): 1323-1328.
[3]	Lei Huang, Kesong Shi, Quanming Jiao, Tao Zhang, Peng Meng. Clinical observation of G-arm assisted plasma radiofrequency ablation combined with ozone in the treatment of inclusive lumbar disc herniation and analysis of the influencing factors of recurrence [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2021, 16(03): 232-238.
[4]	Na Li, Dong Liang, Qinheng Yang. Technical points of radiofrequency ablation for breast tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(05): 380-384.
[5]	Man Li, Ruisha Tu, Shuyong Yu, Xiaojiang Xu, Junfeng Yin. Comparison of ultrasound-guided radiofrequency ablation and minimally invasive endoscopic surgery in the treatment of benign thyroid nodules [J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(01): 31-34.
[6]	Wenjuan Wu, Xiaoli Wang, Juan Liu. Progress of minimally invasive surgery for breast nodules [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(02): 229-232.
[7]	Jianxun Chen. Comparison of the efficacy and complications of three surgical treatments on stage Ⅱ gallbladder cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(04): 418-420.
[8]	Yafeng Chen, Xilin Du, Rui Dong, Jianguo Lu, Li Zang. Efficacy of laparoscopic ultrasound-guided microwave ablation for giant hepatic hemangioma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(04): 333-338.
[9]	Qifeng Chen, Tao Huang, Lujun Shen, Wang Li, Peihong Wu. Relationship between ASTN1 expression and invasion, metastasis, prognosis of hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(03): 278-282.
[10]	Wanyee Lau, Eric Chunhung Lai. Minimally invasive intervention for liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(03): 201-205.
[11]	Jianyuan Hu, Huanwei Chen. Salvage hepatectomy for recurrence of hepatocellular carcinoma after radiofrequency ablation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(04): 335-338.
[12]	Bin Cao, Yin Guo, Panpan Xia, Jiazhen Liu, Jun Wang, Yumin Sun. Treatment strategies for non-paroxysmal atrial fibrillation: a questionnaire from cardiac electrophysiologists engaged in catheter ablation [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(03): 147-153.
[13]	Kulin Li, Jie Zheng, Xiaoyu Liu, Zhiming Yu, Changying Zhang, Xiaoxi Zhao, Xiaoyan Li, Jiaoping Li, Ruxing Wang. Application of magnetic navigation system in catheter ablation of atrial fibrillation [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2022, 10(01): 12-17.
[14]	Xuecheng Wang, Zijun Chen, Yaya Yu, Fenghua Fan, Xin Xie, Yizhang Wu, Dian Cheng, Jian Zhou, Jinbo Yu, Xiaorong Li, Bing Yang, Minglong Chen. The value of high-resolution diffusion-weighted MRI in the diagnosis of asymptomatic cerebral emboli after atrial fibrillation ablation [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2022, 10(01): 2-6.
[15]	Zhiwen Zhang, Zhibo Lei, Muwei Li, Gairong Huang, Shanling Wang, Jingjing Liu, Ting Wang, Danqing Zhao, Haitao Yang. Clinical significance of platelet to lymphocyte ratio in evaluating the recurrence of radiofrequency ablation in patients with atrial fibrillation [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2022, 16(03): 188-192.

Please choose a citation manager

Content to export